# EDGAR Filing Document

**Accession Number:** 0001776985
**File Stem:** 0002123975-26-000002
**Filing Date:** 2026-3
**Character Count:** 13129
**Document Hash:** c0d712290695af8dc5373e3dde0d705a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002123975-26-000002.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0002123975-26-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Sahin Ugur
- **CENTRAL INDEX KEY:** 0002123975

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39081
- **FILM NUMBER:** 26793750

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 55131
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioNTech SE
- **CENTRAL INDEX KEY:** 0001776985
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
- **BUSINESS PHONE:** 0049613190840

**MAIL ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131

## Ex-24

LIMITED POWER OF ATTORNEY

FOR SEC REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of

Zoey Neuenschwander, Stefanie Lutze, and Humza Bokhari, signing singly and each acting

individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as

hereinafter described to:

(1) submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID Application

and/or Passphrase Update Application or any other application materials to enable the undersigned

to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the

SEC;

(2) take any other action of any type whatsoever in connection with the foregoing which, in the

opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by,

the undersigned, it being understood that the documents executed by such attorney-in-fact on

behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and

shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-

fact's discretion;

(3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or

director of BioNTech SE (the "Company"), filings under Section 16 of the Securities Exchange

Act of 1934, Forms 144, and Schedules 13D and 13G, each including any amendments thereto;

(4) do and perform any and all acts for and on behalf of the undersigned which may be necessary

or desirable to prepare, complete and execute any such filings, prepare, complete and execute any

amendment or amendments thereto, and timely deliver and file such form with the SEC and any

stock exchange or similar authority; and

(5) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information

regarding transactions in the Company's securities from any third party, including brokers,

employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such

person to release any such information to such attorney-in-fact and approves and ratifies any such

release of information.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and

perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the

exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the

undersigned might or could do if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute

or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney

and the rights and powers herein granted. The undersigned acknowledges that the foregoing

attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming

nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities

to comply with filing obligations pursuant to Form 144, Schedule 13D, Schedule 13G, Form 3,

Form 4, or Form 5. The undersigned acknowledges that neither the Company nor the foregoing

attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the

beneficial ownership and transaction reporting requirements associated with the foregoing filings

or (ii) any liability of the undersigned for any failure to comply with such requirements.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no

longer required to file any such with respect to the undersigned's beneficial ownership of and

transactions in securities issued by the Company, unless earlier revoked by the undersigned in a

signed writing delivered to the foregoing attorneys-in-fact.

------

[Signature page follows.]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be

executed as of this _____ day of _______________, 2026.

/s/ Ugur Sahin

Name:

[Signature Page to Power of Attorney]

File No. 711 /2025 D.

I hereby certify, that the above signature are the true signature, subscribed in

my presence, of

Prof. Dr. Ugur Sahin,

born [\*\*\*],

business adress: 55131 Mainz, An der Goldgrube 12

- personally known to me –

Upon my inspection of today of the commercial register, I certify that

BioNTech SE

is registered at the Municipal Court of Mainz - Commercial Register - under No. HRB

48720 and that

Prof. Dr. Ugur Sahin, born [\*\*\*],

as this company's Management Board Member,

are registered with the right to jointly act as this company' s legal representatives.

Mainz, 12th of February 2026

[SEAL]

/s/ Mascha Diefenbach

Diefenbach, Notary public

------

[SEAL]

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country:&nbsp;&nbsp;&nbsp;&nbsp;Federal Republic of Germany

This public document

2. has been signed by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mascha Diefenbach

3. acting in the capacity of&nbsp;&nbsp;&nbsp;&nbsp;notary public

4. bears the seal/stamp of&nbsp;&nbsp;&nbsp;&nbsp;Mascha Diefenbach - Notarin in Mainz

Certified

5. at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mainz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. the&nbsp;&nbsp;&nbsp;&nbsp;25.02.2026

7. by the&nbsp;&nbsp;&nbsp;&nbsp;President of the District Court

8. No&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;247/2026

9. Stamp: [SEAL]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Signature:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Thomas Bergmann

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas Bergmann

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Sahin Ugur<br><sub>(Last) (First) (Middle)</sub><br>C/O BIONTECH SE<br>AN DER GOLDGRUBE 12<br><sub>(Street)</sub><br>MAINZ, GERMANY D-55131<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BioNTech SE [ BNTX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Executive Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 40132788 | I | See Footnote<sup>(1)</sup> |
| Ordinary Shares | 858209 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Option (right to buy) | 2027-05-22<sup>(2)</sup> | 2033-05-22 | Ordinary Shares<sup>(3)</sup> | 38506 | 113.94<sup>(4)</sup> | D |  |
| Option (right to buy) | 2028-08-26<sup>(2)</sup> | 2034-08-26 | Ordinary Shares<sup>(3)</sup> | 53233 | <sup>(4)(5)</sup> | D |  |
| Option (right to buy) | 2029-05-28<sup>(2)</sup> | 2035-05-28 | Ordinary Shares<sup>(3)</sup> | 18747 | <sup>(4)(6)</sup> | D |  |
| Phantom Option | 2025-05-12<sup>(2)</sup> | 2031-05-12 | Ordinary Shares<sup>(7)</sup> | 17780 | 185.23<sup>(4)</sup> | D |  |
| Phantom Option | 2026-05-31<sup>(2)</sup> | 2032-05-31 | Ordinary Shares<sup>(7)</sup> | 19997 | 152.10<sup>(4)</sup> | D |  |
| Performance Share Unit | 2029-05-27<sup>(8)</sup> | 2035-05-27 | Ordinary Shares<sup>(8)</sup> | 23434 | $0 | D |  |

---

### Footnotes:

(1) The ordinary shares are held by Medine GmbH. The Reporting Person is the sole shareholder of Medine GmbH. 1,021,398 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The Reporting Person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

(2) The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certainperformance-based and other conditions.

(3) The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

(4) Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

(5) The exercise price of this option is EUR 75.91.

(6) The exercise price of this option is EUR 93.35.

(7) Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.

(8) Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

**Remarks:**
Exhibit List - Exhibit 24 - Power of Attorney

**Signature:** /s/ Humza Bokhari, Attorney-in-Fact  
**Date:** 2026-03-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**